Download our Cancer Research
eBook
Learn how leading researchers are leveraging tools built on synthetic DNA to advance their research in cancer model development, drug discovery, diagnostics, and more.
The Cancer Research Continuum
Whether your goal is to uncover the genetic origins of cancer, engineer a biologic, or detect new biomarkers, you’ll need the proper tools for your research.
Discovery
There is still much needed to discover the fundamental mechanisms driving cancer—how do genetic mutations, cellular pathways, and environmental factors lead to tumor development?
By mapping these intricate biological processes, researchers can identify key oncogenes, tumor suppressors, and signaling networks that contribute to cancer progression.
Therapeutic Development
Cancer therapeutic development involves translating genetic insights into effective treatments, using engineered biological systems, animal testing, and targeted therapies.
To engineer cell and gene therapies, or to build antibodies, you’ll need to first code them in synthetic DNA. Learn more about the tools behind cutting edge therapeutics.
Detection
Detection and diagnostics research focuses on identifying cancer-related genetic mutations and biomarkers for early detection, monitoring, and personalized treatment.
Learn how liquid biopsies, NGS, and AI-driven analysis are enhancing sensitivity and accuracy.
Download our Cancer Research
eBook
Learn how leading researchers are leveraging tools built on synthetic DNA to advance their research in cancer model development, drug discovery, diagnostics, and more.
The Cancer Research Continuum
Whether your goal is to uncover the genetic origins of cancer, engineer a biologic, or detect new biomarkers, you’ll need the proper tools for your research.
Discovery
There is still much needed to discover the fundamental mechanisms driving cancer—how do genetic mutations, cellular pathways, and environmental factors lead to tumor development?
By mapping these intricate biological processes, researchers can identify key oncogenes, tumor suppressors, and signaling networks that contribute to cancer progression.
Therapeutic Development
Cancer therapeutic development involves translating genetic insights into effective treatments, using engineered biological systems, animal testing, and targeted therapies.
To engineer cell and gene therapies, or to build antibodies, you’ll need to first code them in synthetic DNA. Learn more about the tools behind cutting edge therapeutics.
Detection
Detection and diagnostics research focuses on identifying cancer-related genetic mutations and biomarkers for early detection, monitoring, and personalized treatment.
Learn how liquid biopsies, NGS, and AI-driven analysis are enhancing sensitivity and accuracy.
Key Methods for Cancer Research
Learn the fundamental techniques powering modern cancer research through Discovery, Therapeutic Development, and Detection.
-
Detection
Identifying biomarkers for disease detection and characterization
-
Discovery
Uncovering mechanisms of disease and building in vitro models
-
Therapeutic Development
Generating novel treatments
Liquid biopsies are minimally invasive tests that detect cancer-related biomarkers in bodily fluids, enabling early detection, treatment monitoring, and personalized therapy.
Minimally Invasive
Liquid biopsies require only a blood sample, reducing the need for surgical tissue biopsies.
MRD
Minimal residual disease (MRD) testing searches for trace biomarkers that indicate some cancer cells survived treatment.
Early Detection & Precision Medicine
Liquid biopsies can detect cancer at early stages and identify genetic mutations for targeted therapies.
Whole exome sequencing (WES) in cancer research identifies genetic variants in protein-coding and key disease-associated regions in the genome, helping uncover cancer drivers, guide targeted therapies, and advance precision medicine.
Broad Mutation Detection
Identifies cancer-driving mutations across all protein-coding and disease associated regions of the genome.
Precision Medicine Research
Can identify potential targeted therapies based on a tumor’s
genetic profile.
Cost-Effective Compared to WGS
Focuses on exons, which contain most disease-related mutations, making it more efficient for cancer research.
RNA sequencing (RNAseq) in cancer research analyzes gene expression patterns and transcriptomic alterations, providing insights into tumor biology, treatment response, and potential therapeutic targets.
Gene Expression Profiling
Measures how genes are turned on or off in cancer cells, revealing tumor biology and progression.
Splicing & Fusion Detection
Identifies cancer-specific transcript variants, including gene fusions that may serve as therapeutic targets.
Dynamic Insights for PGx
Captures real-time molecular changes to help predict treatment response in pharmacogenomic (PGx) studies.
Gain a holistic understanding of biological processes on a systems level. Synthetic DNA provides the uniform, accurate, raw material needed to power functional genomics.
Single Cell CRISPR
Every cell counts when working with precious samples. Avoid bias, minimise non-functional guides and get the space to encode complex screens with Twist Oligos.
Next Gen CRISPR
Ask unanswered questions of cancer biology by encoding prime editing or combinatorial Cas 12/13 screens in long, uniform oligos.
Genome Wide CRISPR
Build linear or cloned genome-wide or synthetic lethality libraries and systematically link the cancer phenotype and genotype.
Targeted CRISPR Screens
Quickly validate the impact of hits from genome wide screens with gRNA libraries.
PRODUCT OFFERING
GWAS
Identifies cancer-linked variants by comparing affected and unaffected genomes at the population level, requiring streamlined sequencing tools.
Enhancer or Promoter Screens
Synthesize libraries of regulatory DNA elements up to 500 nucleotides in length, without complexity restrictions, and identify new therapeutic targets or drivers of tumor growth.
ClinVar Screens
Encode libraries of clinically relevant genetic variants to assess cancer risk, diagnosis, and treatment options.
PRODUCT OFFERING
Use synthetic DNA to create experimental systems that mimic the behavior of cancer in humans by encoding oncogenes. Alternatively, synthesize genes built to encode gRNA expression cassettes or knock-in templates to generate cell lines with pathogenic mutations.
PRODUCT OFFERING
NGS offers an understanding of cancer biology via comprehensive analysis of mutations, structural variations, and gene expression changes, providing critical insights for cancer classification, progression, and targeted therapy development.
PRODUCT OFFERING
Target ID and validation studies employ genomic, proteomic, and functional screening technologies to pinpoint and validate tumor-specific targets, ensuring they are biologically relevant, druggable, and capable of driving meaningful outcomes.
Next Generation Sequencing (NGS)
Whole-genome or targeted sequencing reveals key tumor mutations for therapeutic targeting.
CRISPR
Precisely edits target proteins to validate their role in disease by knockout or functional rescue.
Advanced high-throughput screening techniques utilizing in vivo or in vitro workflows rapidly identify and validate potential therapeutic molecules that specifically target oncology and immuno-oncology related pathways.
PRODUCT OFFERING
Lead optimization involves refining biotherapeutic candidates to enhance their efficacy, safety, and pharmacological properties, utilizing in silico or engineering techniques such as humanization, affinity maturation, and developability assessments.
PRODUCT OFFERING
Focuses on further profiling and testing optimized antibodies to pick lead candidates including the use of anti-idiotype antibodies to detect specificity and efficacy, ensuring leads are primed for clinical trials by evaluating pharmacokinetics, safety, and potential efficacy against cancer targets.
PRODUCT OFFERING
We’re Here To Help
Every study is unique, and finding the right tools for the job can be tough. Don’t settle for an imperfect solution.
Our experts will help you find the best path forward and advance your studies.
Key Methods for Cancer Research
Learn the fundamental techniques powering modern cancer research through Discovery, Therapeutic Development, and Detection.
-
Detection
Identifying biomarkers for disease detection and characterization
-
Discovery
Uncovering mechanisms of disease and building in vitro models
-
Therapeutic Development
Generating novel treatments
Liquid biopsies are minimally invasive tests that detect cancer-related biomarkers in bodily fluids, enabling early detection, treatment monitoring, and personalized therapy.
Minimally Invasive
Liquid biopsies require only a blood sample, reducing the need for surgical tissue biopsies.
MRD
Minimal residual disease (MRD) testing searches for trace biomarkers that indicate some cancer cells survived treatment.
Early Detection & Precision Medicine
Liquid biopsies can detect cancer at early stages and identify genetic mutations for targeted therapies.
Whole exome sequencing (WES) in cancer research identifies genetic variants in protein-coding and key disease-associated regions in the genome, helping uncover cancer drivers, guide targeted therapies, and advance precision medicine.
Broad Mutation Detection
Identifies cancer-driving mutations across all protein-coding and disease associated regions of the genome.
Precision Medicine Research
Can identify potential targeted therapies based on a tumor’s
genetic profile.
Cost-Effective Compared to WGS
Focuses on exons, which contain most disease-related mutations, making it more efficient for cancer research.
RNA sequencing (RNAseq) in cancer research analyzes gene expression patterns and transcriptomic alterations, providing insights into tumor biology, treatment response, and potential therapeutic targets.
Gene Expression Profiling
Measures how genes are turned on or off in cancer cells, revealing tumor biology and progression.
Splicing & Fusion Detection
Identifies cancer-specific transcript variants, including gene fusions that may serve as therapeutic targets.
Dynamic Insights for PGx
Captures real-time molecular changes to help predict treatment response in pharmacogenomic (PGx) studies.
Gain a holistic understanding of biological processes on a systems level. Synthetic DNA provides the uniform, accurate, raw material needed to power functional genomics.
Single Cell CRISPR
Every cell counts when working with precious samples. Avoid bias, minimise non-functional guides and get the space to encode complex screens with Twist Oligos.
Next Gen CRISPR
Ask unanswered questions of cancer biology by encoding prime editing or combinatorial Cas 12/13 screens in long, uniform oligos.
Genome Wide CRISPR
Build linear or cloned genome-wide or synthetic lethality libraries and systematically link the cancer phenotype and genotype.
Targeted CRISPR Screens
Quickly validate the impact of hits from genome wide screens with gRNA libraries.
PRODUCT OFFERING
GWAS
Identifies cancer-linked variants by comparing affected and unaffected genomes at the population level, requiring streamlined sequencing tools.
Enhancer or Promoter Screens
Synthesize libraries of regulatory DNA elements up to 500 nucleotides in length, without complexity restrictions, and identify new therapeutic targets or drivers of tumor growth.
ClinVar Screens
Encode libraries of clinically relevant genetic variants to assess cancer risk, diagnosis, and treatment options.
PRODUCT OFFERING
Use synthetic DNA to create experimental systems that mimic the behavior of cancer in humans by encoding oncogenes. Alternatively, synthesize genes built to encode gRNA expression cassettes or knock-in templates to generate cell lines with pathogenic mutations.
PRODUCT OFFERING
NGS offers an understanding of cancer biology via comprehensive analysis of mutations, structural variations, and gene expression changes, providing critical insights for cancer classification, progression, and targeted therapy development.
PRODUCT OFFERING
Target ID and validation studies employ genomic, proteomic, and functional screening technologies to pinpoint and validate tumor-specific targets, ensuring they are biologically relevant, druggable, and capable of driving meaningful outcomes.
Next Generation Sequencing (NGS)
Whole-genome or targeted sequencing reveals key tumor mutations for therapeutic targeting.
CRISPR
Precisely edits target proteins to validate their role in disease by knockout or functional rescue.
Advanced high-throughput screening techniques utilizing in vivo or in vitro workflows rapidly identify and validate potential therapeutic molecules that specifically target oncology and immuno-oncology related pathways.
PRODUCT OFFERING
Lead optimization involves refining biotherapeutic candidates to enhance their efficacy, safety, and pharmacological properties, utilizing in silico or engineering techniques such as humanization, affinity maturation, and developability assessments.
PRODUCT OFFERING
Focuses on further profiling and testing optimized antibodies to pick lead candidates including the use of anti-idiotype antibodies to detect specificity and efficacy, ensuring leads are primed for clinical trials by evaluating pharmacokinetics, safety, and potential efficacy against cancer targets.
PRODUCT OFFERING
We’re Here To Help
Every study is unique, and finding the right tools for the job can be tough. Don’t settle for an imperfect solution.
Our experts will help you find the best path forward and advance your studies.
Featured Resources
Twist products are for research use only. The products presented here are not intended for the diagnosis, prevention, or treatment of a disease or condition. Twist Bioscience assumes no liability regarding use of the product for applications in which it is not intended. The results are specific to the institution to which they were obtained. The results presented are customer-specific and should not be interpreted as indicative of performance across all institutions.
Featured Resources
Twist products are for research use only. The products presented here are not intended for the diagnosis, prevention, or treatment of a disease or condition. Twist Bioscience assumes no liability regarding use of the product for applications in which it is not intended. The results are specific to the institution to which they were obtained. The results presented are customer-specific and should not be interpreted as indicative of performance across all institutions.
